作者
Pavlo Gilchuk, Natalia Kuzmina, Philipp A Ilinykh, Kai Huang, Bronwyn M Gunn, Aubrey Bryan, Edgar Davidson, Benjamin J Doranz, Hannah L Turner, Marnie L Fusco, Matthew S Bramble, Nicole A Hoff, Elad Binshtein, Nurgun Kose, Andrew I Flyak, Robin Flinko, Chiara Orlandi, Robert Carnahan, Erica H Parrish, Alexander M Sevy, Robin G Bombardi, Prashant K Singh, Patrick Mukadi, Jean Jacques Muyembe-Tamfum, Melanie D Ohi, Erica Ollmann Saphire, George K Lewis, Galit Alter, Andrew B Ward, Anne W Rimoin, Alexander Bukreyev, James E Crowe
发表日期
2018/8/21
期刊
Immunity
卷号
49
期号
2
页码范围
363-374. e10
出版商
Elsevier
简介
Ebolaviruses cause severe disease in humans, and identification of monoclonal antibodies (mAbs) that are effective against multiple ebolaviruses are important for therapeutics development. Here we describe a distinct class of broadly neutralizing human mAbs with protective capacity against three ebolaviruses infectious for humans: Ebola (EBOV), Sudan (SUDV), and Bundibugyo (BDBV) viruses. We isolated mAbs from human survivors of ebolavirus disease and identified a potent mAb, EBOV-520, which bound to an epitope in the glycoprotein (GP) base region. EBOV-520 efficiently neutralized EBOV, BDBV, and SUDV and also showed protective capacity in relevant animal models of these infections. EBOV-520 mediated protection principally by direct virus neutralization and exhibited multifunctional properties. This study identified a potent naturally occurring mAb and defined key features of the human …
学术搜索中的文章
P Gilchuk, N Kuzmina, PA Ilinykh, K Huang, BM Gunn… - Immunity, 2018